NASDAQ · BEAM
Healthcare · Biotechnology
$26.75
Up+$0.24 (+0.91%)
Updated Aug 15, 2026, 6:53 PM
SID Score
4.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
BEAM closed at $26.75 after 21 trading sessions, down 2.83% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $26.64 | $26.88 | $25.71 | $26.75 | 1.23M |
| Aug 13, 2026 | $27.26 | $27.4888 | $26.26 | $26.51 | 2.02M |
| Aug 12, 2026 | $27.00 | $27.31 | $26.62 | $26.71 | 1.55M |
| Aug 11, 2026 | $27.45 | $27.565 | $26.53 | $26.85 | 1.33M |
| Aug 10, 2026 | $27.46 | $27.95 | $27.11 | $27.28 | 1.25M |
| Aug 7, 2026 | $27.71 | $28.35 | $27.13 | $27.48 | 1.32M |
| Aug 6, 2026 | $26.71 | $27.99 | $26.56 | $27.25 | 1.17M |
| Aug 5, 2026 | $28.42 | $28.47 | $26.62 | $27.07 | 2.06M |
| Aug 4, 2026 | $26.73 | $28.42 | $26.42 | $28.35 | 2.15M |
| Aug 3, 2026 | $25.545 | $26.25 | $24.67 | $25.91 | 1.3M |
| Jul 31, 2026 | $26.83 | $26.933 | $25.3563 | $25.52 | 1.07M |
| Jul 30, 2026 | $26.03 | $26.52 | $25.37 | $26.49 | 1.45M |
| Jul 29, 2026 | $26.19 | $27.02 | $25.65 | $26.02 | 1.58M |
| Jul 28, 2026 | $25.00 | $26.30 | $24.67 | $26.29 | 2.3M |
| Jul 27, 2026 | $25.448 | $26.105 | $25.04 | $25.07 | 1.82M |
| Jul 24, 2026 | $26.22 | $26.41 | $24.85 | $25.10 | 1.81M |
| Jul 23, 2026 | $26.00 | $26.655 | $25.68 | $25.91 | 2.96M |
| Jul 22, 2026 | $26.92 | $27.17 | $26.47 | $26.64 | 1.55M |
| Jul 21, 2026 | $26.50 | $27.77 | $26.10 | $27.29 | 1.85M |
| Jul 20, 2026 | $27.75 | $28.13 | $26.19 | $26.33 | 2.77M |
| Jul 17, 2026 | $27.37 | $28.51 | $27.10 | $27.53 | 1.91M |
The latest Smart Investors Daily articles mentioning BEAM.
BEAM research
Company profile and research snapshot.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 8, 2026 | B of A Securities | Buy | — |
| Jul 7, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Bernstein | Outperform | — |
| Mar 26, 2026 | Citigroup | Buy | — |
| Feb 25, 2026 | RBC Capital | Sector Perform | — |
No generated briefing is available yet.
Benzinga · Aug 4, 2026
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.11) by 6.31 percent. This is a 18 percent decrease over losses of $(1.00) per share from
SeekingAlpha · Aug 3, 2026
Beam Therapeutics (BEAM) stock outlook: gene-editing pipeline, strong cash runway to 2029, and conservative valuation.
Benzinga · Jul 23, 2026
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the Phase 1/2 trial
SeekingAlpha · Jul 16, 2026
The curing sickle cell through gene therapy story is a long way from being written. But itâs for sure that it has not gone like some of its participants have wanted it to. Read more here...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BEAM.
